BYSI vs. CRDF, IMMP, NGNE, OLMA, AQST, AVIR, FHTX, ACB, NMRA, and AMLX
Should you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Cardiff Oncology (CRDF), Immutep (IMMP), Neurogene (NGNE), Olema Pharmaceuticals (OLMA), Aquestive Therapeutics (AQST), Atea Pharmaceuticals (AVIR), Foghorn Therapeutics (FHTX), Aurora Cannabis (ACB), Neumora Therapeutics (NMRA), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.
BeyondSpring vs.
Cardiff Oncology (NASDAQ:CRDF) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, community ranking, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
BeyondSpring has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,238.17%. BeyondSpring's return on equity of 0.00% beat Cardiff Oncology's return on equity.
Cardiff Oncology currently has a consensus price target of $11.67, suggesting a potential upside of 191.67%. Given Cardiff Oncology's stronger consensus rating and higher possible upside, research analysts plainly believe Cardiff Oncology is more favorable than BeyondSpring.
BeyondSpring received 143 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 66.79% of users gave BeyondSpring an outperform vote while only 64.62% of users gave Cardiff Oncology an outperform vote.
16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 40.3% of BeyondSpring shares are owned by institutional investors. 7.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 29.3% of BeyondSpring shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
BeyondSpring has higher revenue and earnings than Cardiff Oncology.
In the previous week, Cardiff Oncology and Cardiff Oncology both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.87 beat Cardiff Oncology's score of 0.94 indicating that BeyondSpring is being referred to more favorably in the news media.
Cardiff Oncology has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.
Summary
BeyondSpring beats Cardiff Oncology on 10 of the 15 factors compared between the two stocks.
Get BeyondSpring News Delivered to You Automatically
Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BeyondSpring Competitors List
Related Companies and Tools
This page (NASDAQ:BYSI) was last updated on 3/16/2025 by MarketBeat.com Staff
